PMID- 37130184
OWN - NLM
STAT- MEDLINE
DCOM- 20230504
LR  - 20230504
IS  - 1165-158X (Electronic)
IS  - 0145-5680 (Linking)
VI  - 68
IP  - 12
DP  - 2022 Dec 31
TI  - Relationship between Abdominal Obesity and Insulin Resistance, Growth Hormone, 
      and Insulin-like Growth Factor-1 in Individuals with Type 2 Diabetes.
PG  - 36-41
LID - 10.14715/cmb/2022.68.12.8 [doi]
AB  - This experiment was designed to investigate the correlation between abdominal 
      obesity and insulin resistance (IR), growth hormone (GH) and insulin-like growth 
      factor-1 (IGF-1) in patients with type 2 diabetes mellitus (T2DM). To do this 
      experiment, 200 patients with T2DM were enrolled in this cross-sectional study. 
      They were divided into the control group (T2DM without abdominal obesity) and the 
      observation group (T2DM combined with abdominal obesity) according to the 
      diagnostic criteria of abdominal obesity. General data and biochemical indices 
      were recorded from all patients. Results showed that 97 patients (48.50%, 97/200) 
      with abdominal obesity were included in the observation group, and 103 patients 
      (51.50%,103/200) without abdominal obesity were included in the control group. 
      Meanwhile, the body weight, BMI, waist circumference and waist-to-hip ratio were 
      higher in the observation group than in the control group (P<0.05). Meanwhile, 
      the visceral fat in the observation group, TC, and TG were higher (P<0.05) 
      compared with the control group (Visceral Fat, 92.55+/-3.07 vs 87.63+/-3.14. TC, 
      5.14+/-0.48 vs 4.97+/-0.51), and TG,1.89+/-0.13 vs 1.53+/-0.16). In addition, the levels 
      of FBG, FINS and HOMA-IR were higher (P<0.05) in the observation group than those 
      in the control group (FBG, 13.06+/- 2.17 vs 10.62+/-2.35. FINS, 16.25+/-2.14 vs 
      13.33+/-3.21. HOMA-IR, 9.43+/-1.90 vs 6.29+/-2.10). However, the levels of GH and IGF-1 
      were lower (P<0.05) in the observation group than those in the control group (GH, 
      1.16+/-0.08 vs 1.24+/-0.11. IGF-1, 125.14+/-11.46 vs 135.71+/-12.33). Spearman's 
      correlation analysis showed that abdominal obesity was positively correlated with 
      IR (R0.372, P=0.000) in patients with T2DM, while negatively correlated with GH 
      (R=-0.271, P=0.000) and IGF-1(R-0.219, P=0.000) levels. In conclusion, abdominal 
      obesity in patients with T2DM is positively associated with IR, and negatively 
      correlated with GH and IGF-1 levels. Thus, improvement of IR as well as 
      regulating the levels of growth hormone and IGF-1 might play crucial roles in the 
      early prevention and efficient clinical treatment of T2DM with abdominal obesity 
      patients.
FAU - Lu Wen
AU  - Lu Wen
AD  - Department of Endocrinology, General Hospital of Central Theater Command, Wuhan, 
      Hubei, China. Wenluwh@163.com.
FAU - Cheng Chen
AU  - Cheng Chen
AD  - Department of Endocrinology, Asia general Hospital, Wuhan, Hubei, China. 
      luw202210@163.com.
FAU - Keji Zhou
AU  - Keji Zhou
AD  - Department of Endocrinology, Wuhan university of technology Hospital, Wuhan, 
      Hubei, China. kejizhou2022@163.com.
LA  - eng
PT  - Journal Article
DEP - 20221231
PL  - France
TA  - Cell Mol Biol (Noisy-le-grand)
JT  - Cellular and molecular biology (Noisy-le-Grand, France)
JID - 9216789
RN  - 9002-72-6 (Growth Hormone)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 12629-01-5 (Human Growth Hormone)
RN  - 0 (Insulin)
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Humans
MH  - *Insulin Resistance
MH  - Growth Hormone
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Obesity, Abdominal/complications
MH  - Insulin-Like Growth Factor I
MH  - Cross-Sectional Studies
MH  - Body Mass Index
MH  - Obesity/complications
MH  - *Human Growth Hormone
MH  - Insulin
MH  - Blood Glucose
EDAT- 2023/05/02 18:41
MHDA- 2023/05/04 12:42
CRDT- 2023/05/02 14:11
PHST- 2022/10/24 00:00 [received]
PHST- 2023/05/04 12:42 [medline]
PHST- 2023/05/02 18:41 [pubmed]
PHST- 2023/05/02 14:11 [entrez]
AID - 10.14715/cmb/2022.68.12.8 [doi]
PST - epublish
SO  - Cell Mol Biol (Noisy-le-grand). 2022 Dec 31;68(12):36-41. doi: 
      10.14715/cmb/2022.68.12.8.